Get the Stockscreener App
0.478
8.09%
-0.0421
Lucid Diagnostics Inc stock is traded at $0.478, with a volume of 2.33M.
It is down -8.09% in the last 24 hours and down -42.85% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.5201
Open:
$0.5224
24h Volume:
2.33M
Relative Volume:
1.20
Market Cap:
$91.27M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-0.5805
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
-25.08%
1M Performance:
-42.85%
6M Performance:
-61.76%
1Y Performance:
-61.14%
1-Day Range:
$0.4702
$0.5255
1-Week Range:
$0.4702
$0.66
52-Week Range:
$0.4702
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.478 | 91.27M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Finansavisen
A new billing code was approved for a tool that collects esophageal cells. Medicare payment remains pending. - Stock Titan
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Yahoo Finance
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9.5 - Moomoo
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Benzinga
LUCD Q1 2026 Earnings: EPS Misses by 100.7% as Commercialization Costs MountROIC Trend Report - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - Yahoo Finance
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93Imbalance Zone - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportUnusual Put Volume - vinanet.vn
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Lucid Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Nigeria
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com India
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Canada
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com UK
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):